C hronic infection with hepatitis C virus (HCV) is a major public health problem, affecting 2-4 million people in the United States. 1 Chronic HCV is a leading cause of cirrhosis, hepatocellular carcinoma, and death from liver disease. In fact, HCV is associated with more deaths than 60 other infectious diseases combined, including human immunodeficiency virus and tuberculosis. 2 The availability of oral direct-acting antivirals (DAAs) since 2014 has changed the HCV treatment paradigmthese therapies are highly effective and have shorter treatment durations and fewer adverse effects than older therapies do. All major clinical guidelines recommend treating all eligible chronic HCV patients with DAAs. 3 
HCV Elimination
Recent advances in HCV treatment offer an unprecedented opportunity to eliminate HCV. In 2016, the World Health Assembly pledged to eliminate HCV as a public health threat (ie, 90% reduction in HCV incidence and 65% reduction in HCV mortality) by 2030. To achieve HCV elimination, the World Health Organization (WHO) launched a global strategy with an ambitious goal of diagnosing 90% of HCV-infected people and treating 80% of all eligible people. 4 Similarly, the National Academies of Science, Engineering, and Medicine launched a national strategy to eliminate HCV in the United States. 5 This noble undertaking will require several paradigm changes including expanded testing, universal access to treatment, and a focus on public health rather than on the individual patient. Changing the overarching goal of the U.S. health care system from caring for a patient to maintaining the health of a population will require time and considerable effort. 6 A key element in HCV elimination is patient awareness-approximately 50% of HCV-infected persons do not know they are infected. 7 Additionally, new HCV cases continue to increase-the CDC reported that HCV incidence has nearly tripled over the last 5 years, reaching a 15-year high, at 41,200 new cases in 2016. 8 The "new" epidemic is primarily in persons below 30 years of age. 9 Injection drug use being the primary risk factor for new HCV infections, an important step in eliminating HCV must involve controlling the spread of HCV in these young persons who inject drugs (PWID). Though current guidelines recommend one-time HCV testing for anyone born between 1945 and 1965 and targeted HCV testing of PWID, 10 history has proven targeted screening ineffective. Hence, we suspect that the current policy will fail to identify many of the more than a million HCV patients not aware of their infection. 11 Therefore, updates in screening recommendations are needed to eliminate HCV. In addition, to allocate resources wisely, the new policy should weigh the cost and benefits.
Does Universal HCV Screening Provide a Good Value for Money?
To fill evidence gaps, Eckman et al, 12 in this issue of Clinical Gastroenterology and Hepatology, evaluated the cost effectiveness of one-time universal screening for HCV in all adults in the United States. They developed a decision-analytic model to simulate the natural history of HCV and used it to evaluate long-term outcomes of universal screening versus status quo. Patients diagnosed with HCV were treated with DAAs.
Model outcomes included quality-adjusted life-years (QALYs), which account for both the quality and quantity of life lived; total costs that include the cost of screening, treatment, downstream events (eg, decompensated cirrhosis, liver transplantation), and the incremental cost-effectiveness ratio (ICER), which estimates the additional amount needed to gain one additional QALY. The calculation was used to determine if universal HCV screening is cost-effective. The study found that the ICER of universal HCV screening in the United States is $11,400 per QALY gained. Interventions are deemed cost effective if the value of the ICER is below a predetermined willingness-to-pay threshold-typically $100,000 per QALY in the United States. Therefore, by the current yardstick, universal HCV screening provides good value for money.
Independent modeling studies validating the conclusions of Eckman et al 12 could encourage policymakers to make changes in the current screening practice. In addition, future modeling studies could fill gaps in their analysis by considering the value of repeated HCV screening in young high-risk groups, benefits of antiviral treatment in reducing HCV transmission, the potential impact of universal screening on averting HCV-related transmission, and budget impact of universal screening.
An important step in eliminating HCV is controlling the spread of HCV in PWID. Though current recommendations include screening of PWID, they have failed to reduce ongoing transmission. Reasons for failure include low screening rates, low treatment uptake, and reinfection after successful treatment. Several of these reasons will remain applicable in universal screening. Though we may hope that the uptake of HCV testing in PWID will increase with the implementation of universal screening, sustained efforts will be needed to scale up screening and treatment and to avoid reinfection. 13 Both screening and treatment policy will require revision. The admonition to screen PWID ignores the fact that a large part of this population exists outside standard medical care-universal screening will require aggressive outreach efforts by health care agencies. For treatment, policymakers will have to ignore calls to punish PWID in favor of a practical approach-we will not eliminate HCV if we fail to treat HCV infection in this population. An alternative way of thinking is that treating a person who actively uses drugs will prevent him or her from infecting other PWID and thus reduce the reservoir of infected persons and increase return on investment. We also have to get away from the notion of "one and done"; PWID who are reinfected need treatment to diminish downstream infections. Some might say that reinfection is a sign that we are (finally) targeting the correct population. Last, harm reduction strategies such as needle exchange and increased access to opioid agonist therapy among PWID will reduce the transmission of HCV.
14 Implementing universal HCV screening needs planning, resources, and will. HCV is a slow progressive disease; therefore, the benefits of treatment are accrued long after patients achieve cure. Because of this, the fragmented health insurance system in the United States can create barriers to scaling up HCV testing and treatment. For instance, payers providing treatment may not avail the benefits, such as prevention of decompensated cirrhosis, hepatocellular carcinoma, and liver transplant, which will occur decades after treatment; those benefits could be reaped by other payers if patients' insurance status change soon after treatment. To overcome such barriers, HCV testing should occur as part of an individual's routine healthcare visit. In addition, HCV tests should be offered either at no cost or at little cost irrespective of patient's insurance status.
Another barrier to HCV elimination is the budget needed to scale up HCV treatment. At the time of their launch, the listed price of DAAs was between $54,000 and $96,000 per treatment course. However, the effective price of DAAs has come down substantially to below $24,000. At this price, treatment with DAAs is highly cost effective or even cost saving. 15 However, the cost of providing treatment to newly diagnosed HCV patients under universal screening could further strain the budget of several state Medicaid programs, which have already restricted treatment to patients with more advanced liver disease. Innovative financing mechanisms are needed to scale up HCV treatment, especially among Medicaid beneficiaries. 16 For instance, several states are evaluating the feasibility of subscription-type payment model in which the state pays a fixed annual amount to the manufacture in exchange for unlimited access to DAAs during a specified time. 17 In conclusion, in the era of DAAs, we have an opportunity to eliminate HCV by taking appropriate steps. Evidence-based updates in HCV screening policies are needed to prevent HCV-related deaths, reduce ongoing HCV transmission, and diagnose and treat HCV patients who otherwise would remain unaware of their infection. 
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